Unknown

Dataset Information

0

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.


ABSTRACT:

Background

Despite the acknowledged predictive value of KRAS in immune checkpoint inhibitor (ICI) responses, the heterogeneous behavior of its mutations in this sphere remains largely unexplored. As of now, no studies have definitively categorized KRAS subtype variations as independent prognostic indicators for ICI responses in lung cancer patients.

Methods

We analyzed a cohort of 103 patients, all harboring different KRAS mutation subtypes, and complemented this data with information from TCGA and GEO databases. Our research focused on delineating the relationships between KRAS mutation subtypes and factors like immunotherapy markers and immune cell composition, in addition to examining survival rates, drug sensitivity, and PD-L1 responses corresponding to distinct KRAS subtypes.

Results

We found that the G12V and G12D subtypes demonstrated elevated expressions of immunotherapy markers, implying a potentially enhanced benefit from immunotherapy. Significant variations were identified in the distribution of naive B cells, activated CD4+ memory T cells, and regulatory T cells (Tregs) across different KRAS mutant subtypes. A notable difference was observed in the Tumor Mutation Burden (TMB) levels across the four KRAS subtypes, with the G12D subtype displaying the lowest TMB level. Furthermore, G12C subtype showcased the worst prognosis in terms of progression-free intervals (PFI), in stark contrast to the more favorable outcomes associated with the G12A subtype.

Conclusion

Our study reveals that KRAS mutations exhibit considerable variability in predicting outcomes for LUAD patients undergoing ICI treatment. Thus, the evaluation of KRAS as a biomarker for ICIs necessitates recognizing the potential diversity inherent in KRAS mutations.

SUBMITTER: Wang Q 

PROVIDER: S-EPMC10635421 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.

Wang Qi Q   Tang Zhuoran Z   Li Chunyu C   Li Xuefei X   Su Chunxia C  

Frontiers in immunology 20231024


<h4>Background</h4>Despite the acknowledged predictive value of KRAS in immune checkpoint inhibitor (ICI) responses, the heterogeneous behavior of its mutations in this sphere remains largely unexplored. As of now, no studies have definitively categorized KRAS subtype variations as independent prognostic indicators for ICI responses in lung cancer patients.<h4>Methods</h4>We analyzed a cohort of 103 patients, all harboring different KRAS mutation subtypes, and complemented this data with informa  ...[more]

Similar Datasets

| S-EPMC7066911 | biostudies-literature
| S-EPMC11190466 | biostudies-literature
| S-EPMC6197714 | biostudies-literature
| S-EPMC10859432 | biostudies-literature
| S-EPMC6993216 | biostudies-literature
| S-EPMC8757482 | biostudies-literature
| S-EPMC7713997 | biostudies-literature
| S-EPMC8190489 | biostudies-literature
| S-EPMC10000735 | biostudies-literature
| S-EPMC11300455 | biostudies-literature